论文部分内容阅读
目的研究多巴胺受体激动剂－Ｐｅｒｇｏｌｉｄｅ对１３例经复方左放多巴治疗疗效不佳、并伴有症状波动、运动障碍的帕金森病患者临床疗效及安全性。方法采用改良Ｗｅｂｓｔｅｒ评分标准及开放性自身治疗前后对照，评估Ｐｅｒｇｄｉｄｅ治疗后的疗效及安全性。结果显示“开”期潜伏期缩短３２．３ｍｉｎ，改善４２．４％；“开”期持续时间增加１小时，改善４０．０％；Ｈｏｅｈｎ－Ｙａｈｒ分级降低０．７级；改善１９．４％；Ｗｅｂｓｔｅｒ评分减低４．６分，改善３０．５％。有效率４６．２％。统计学处理均有显著性差异（Ｐ＜０．０５）。不良反应轻微。结论Ｐｅｒｇｏｌｉｄｅ是一种安全有效的治疗帕金森病药物。
Objective To study the clinical efficacy and safety of dopamine receptor agonist-bergolide in 13 patients with Parkinson’s disease who had poor response and complicated with symptoms and dyskinesia. Methods The modified Webster score and open self-control before and after treatment were compared to evaluate the efficacy and safety of Pergdide treatment. The results showed that the incubation period of “open” period was shortened by 32.3min and improved by 42.4%; the duration of “on” period increased by 1 hour and the improvement was 40.0%; the Hoehn-Yahr classification was reduced by 0.7 and the improvement was 19.4% Webster scored 4.6 points lower, an improvement of 30.5%. Effective 46.2%. Statistical analysis showed significant differences (P <0.05). Minor adverse reactions. Conclusion Pergolide is a safe and effective drug for the treatment of Parkinson’s disease.